How GlycoMimetics Inc’s (NASDAQ:GLYC) EPS Growth Stacks Up Against Industry Performance

Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at GlycoMimetics Inc’s (NASDAQ:GLYC) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. View our latest analysis for GlycoMimetics

Commentary On GLYC’s Past Performance

For the purpose of this commentary, I like to use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. This blend enables me to analyze different stocks in a uniform manner using the latest information. For GlycoMimetics, the latest earnings -$32.4M, which compared to the prior year’s level, has become less negative. Given that these values are somewhat myopic, I have computed an annualized five-year value for GlycoMimetics’s earnings, which stands at -$14.8M. This means GlycoMimetics has historically performed better than recently, although it seems like earnings are now heading back towards to right direction again.

NasdaqGM:GLYC Income Statement Dec 13th 17
NasdaqGM:GLYC Income Statement Dec 13th 17
We can further evaluate GlycoMimetics’s loss by looking at what’s going on in the industry along with within the company. First, I want to quickly look into the line items. Revenue growth over last couple of years has been negative at -16.08%. The key to profitability here is to make sure the company’s cost growth is well-controlled. Eyeballing growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% in the previous year, and 20.18% over the past five years. This shows that any tailwind the industry is enjoying, GlycoMimetics has not been able to reap as much as its average peer.

What does this mean?

Though GlycoMimetics’s past data is helpful, it is only one aspect of my investment thesis. Companies that incur net loss is always hard to predict what will occur going forward, and when. The most useful step is to assess company-specific issues GlycoMimetics may be facing and whether management guidance has dependably been met in the past. I recommend you continue to research GlycoMimetics to get a better picture of the stock by looking at:

1. Future Outlook: What are well-informed industry analysts predicting for GLYC’s future growth? Take a look at our free research report of analyst consensus for GLYC’s outlook.

2. Financial Health: Is GLYC’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.

3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.